Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The 2020 ACR Review Course: Key Issues Rheumatologists Face

Jason Liebowitz, MD, FACR  |  Issue: January 2021  |  December 17, 2020

ACR Convergence graphicSeronegatives & Psoriatics: Navigating Therapy
Christopher Ritchlin, MD, MPH, MACR, professor and chief of the Allergy, Immunology, and Rheumatology Division at the University of Rochester Medical Center, N.Y., spoke on Seronegatives and Psoriatics: Navigating Therapy. In this wide-ranging presentation, Dr. Ritchlin discussed current and future treatment directions for psoriatic arthritis, inflammatory bowel disease (IBD) associated arthritis and reactive arthritis.

Dr. Ritchlin noted that psoriatic arthritis is a complex, heterogeneous disease that perhaps should be best understood through the lens of the different domains it can involve, such as skin, nails, peripheral arthritis, axial disease, enthesitis and dactylitis. The 2018 ACR/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis provides a clear framework for how to approach therapy in this disease, as well as the means by which to determine severity of disease and the evidence to support treatment recommendations.14

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Turning to enteropathic arthritis, Dr. Ritchlin noted that IBD prevalence in spondyloarthritis is about 7% and that ankylosing spondylitis prevalence in IBD is between 10% and 39%.

When thinking about treatment options, it is important to separate patients with IBD in the form of Crohn’s disease from those with ulcerative colitis and, likewise, to differentiate between peripheral arthritis and axial arthritis. These distinctions are important because each may imply different types of effective therapy; for instance, methotrexate appears to be an option in Crohn’s disease and peripheral arthritis, but not in ulcerative colitis or axial arthritis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For reactive arthritis, the majority of patients will reach complete or near complete remission at 6 to 12 months regardless of therapy, but approximately 25% of patients develop chronic disease and require ongoing therapy. Such treatment for chronic disease may take the form of nonsteroidal anti-inflammatory drugs, intra-articular or systemic glucocorticoids, sulfasalazine, methotrexate or tumor necrosis factor inhibitors.

Rheumatoid Arthritis
Arthur Kavanaugh, MD, professor of medicine and director of the Center for Innovative Therapy in the Division of Rheumatology, Allergy & Immunology at the University of California, San Diego, discussed rheumatoid arthritis and reflected on the dramatic changes he has seen in the field over the past several decades. A number of studies were discussed, but perhaps most helpful were the larger questions that Dr. Kavanaugh pondered regarding future directions in rheumatoid arthritis: Will automated scoring systems for radiographic progression of disease replace human interpretation of X-rays and other imaging studies? Will big data and smart technology allow for methods by which to track patient compliance with prescribed medications? Will useful biomarkers of disease be developed and used to evaluate clinical activity in rheumatoid arthritis? Will biosimilars help to reduce the cost of biologic medications in the U.S. and around the world?

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone DisordersPediatric ConditionsVasculitis Tagged with:ACR Convergence 2020liver diseasemeeting reportsOsteoporosisPediatricpregnancyVasculitis

Related Articles

    TNF Blockade for SLE

    September 1, 2010

    Reckless approach versus missed opportunity?

    Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population

    October 10, 2016

    The following summary regarding use of tacrolimus (TAC) in lupus nephritis highlights a number of debatable points. Although the role of TAC in lupus nephritis remains unproved for North American populations, it might be an excellent option in some clinical situations. These situations include lupus flare during pregnancy and also for lupus nephritis when the…

    State-of-the-Art Approaches to Rheumatic Disease Diagnosis, Management & Treatment

    March 19, 2019

    CHICAGO—Held during the 2018 ACR/ARHP Annual Meeting, the ACR Review Course covered a wide range of topics for rheumatologists—from advances in pain and rheumatic disease management to the intersection of rheumatology and neurology. Session speakers shared insights, as well as state-of-the-art approaches to diagnosis, management and treatment. Inflammatory Myopathies Julie J. Paik, MD, MHS, assistant…

    Lupus Nephritis: Understanding the Paradigm for Treatment

    June 16, 2020

    ACR BEYOND LIVE—Among patients with systemic lupus erythematosus (SLE), lupus nephritis remains one of the leading causes of mortality, and patients with both SLE and end-stage renal disease demonstrate standardized mortality ratios higher than 60 times that of patients with SLE who have normal kidney function.1 Although the ACR Guidelines for Screening, Treatment, and Management…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences